Page 11 - P4304.1-V115 PS Magazine November 2025

To illustrate this – we can look at the recently launched Dapagliflozin. When the brand came
off patent and this line was launched, its price dropped dramatically. Once the tipping point
was reached, where the generic became more profitable than the brand, dispensing doctors
began prescribing and purchasing generically.

Most schemes had high early-month pricing that declined throughout the month. With APM,
every PSUK member was rebated down to the final net price, regardless of when they bought,
maximising profit and protecting margin .

Protection when prices rise

APM isn’t just about falling prices. When the market pricing shifts upward, our agreements
with key partners allow us to secure several months worth of stock on volatile lines through our
‘key generic bins’—holding prices longer and shielding members from stock shortages
and sudden hikes. Net Price

Here’s an example:

Dapagliflozin Launch
When this came off patent, prices plummeted. Other schemes left
early buyers stuck with higher costs.
With APM, every PSUK member was rebated down to the lowest price
maximising profit and protecting margin.

The above demonstrates the average reimbursement on xx is xx% lower, so cash profit will
naturally falls with it. This further establishes that now more than ever it’s more important to
work with PSUK to ensure you are looking after the losses on brands.

13/10/2025 14:03:21
P4304.1-V115 PS Magazine November 2025.indd 11
P4304.1-V115 PS Magazine November 2025.indd 11 13/10/2025 14:03:21